08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Lomitapide: Additional Phase III data

Additional data from 23 evaluable patients who completed 78 weeks of treatment in a single-arm, open-label, international Phase III trial showed that oral lomitapide titrated up to 60 mg/day reduced mean LDL-C by 38.4% from...
07:00 , Sep 12, 2011 |  BioCentury  |  Product Development

Reviving CETP

Evidence is accumulating that the next generation of CETP inhibitors may be able to avoid the off-target effects that doomed Pfizer Inc.'s torcetrapib. Roche reported Phase IIb data in late August showing its dalcetrapib increased HDL...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

Lomitapide: Additional Phase III data

Data from a completer analysis of 23 evaluable patients in a single-arm, open-label, international Phase III trial showed that oral lomitapide titrated up to 60 mg/day reduced mean LDL-C by 50.2% from baseline to week...
07:00 , Jun 7, 2010 |  BioCentury  |  Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E, a protein that can target two additional hepatic receptors capable of clearing...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

GFT505: Phase II data

In the 28-day, double-blind, international Phase IIa GFT505-2083 trial in 97 pre-diabetics with atherogenic dyslipidemia and abdominal obesity, 80 mg/day oral GFT505 met the co-primary endpoints and multiple secondary endpoints. On the co-primary endpoints, GFT505...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Lomitapide: Additional Phase III data

Additional data from an ongoing, open-label Phase III trial in 14 evaluable patients treated for at least 26 weeks showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 49%. Average baseline LDL-C...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Lomitapide: Interim Phase III data

Interim data from 10 evaluable patients treated for at least 6 months in an ongoing, open-label Phase III trial showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 44%. Average baseline LDL-C...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

GFT505: Phase II start

Next half, Genfit will start a double-blind, placebo-controlled, international Phase II trial (Study 2083) to evaluate 80 mg/day of oral GFT505 in 90 patients with abdominal obesity for 28 days. Genfit S.A. (Euronext:ALGFT), Lille, France...
08:00 , Dec 18, 2008 |  BC Innovations  |  Distillery Techniques

This week in techniques

The Distillery: Techniques Approach Summary Licensing status Publication and contact information Markers Assessment of pulmonary arterial hypertension...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

AEGR-733: Preliminary Phase III data

Preliminary data from an ongoing, open-label, Phase III trial in 25 patients showed that AEGR-733 titrated up to 60 mg/day was well tolerated and reduced LDL-C by >50% in the majority of patients that reached...